Publication:
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

dc.contributor.authorsSchmoll, H. J.; Van Cutsem, E.; Stein, A.; Valentini, V.; Glimelius, B.; Haustermans, K.; Nordlinger, B.; van de Velde, C. J.; Balmana, J.; Regula, J.; Nagtegaal, I. D.; Beets-Tan, R. G.; Arnold, D.; Ciardiello, F.; Hoff, P.; Kerr, D.; Koehne, C. H.; Labianca, R.; Price, T.; Scheithauer, W.; Sobrero, A.; Tabernero, J.; Aderka, D.; Barroso, S.; Bodoky, G.; Douillard, J. Y.; El Ghazaly, H.; Gallardo, J.; Garin, A.; Glynne-Jones, R.; Jordan, K.; Meshcheryakov, A.; Papamichail, D.; Pfeiffer, P.; Souglakos, I.; Turhal, S.; Cervantes, A.
dc.date.accessioned2022-03-14T10:55:15Z
dc.date.accessioned2026-01-11T11:22:42Z
dc.date.available2022-03-14T10:55:15Z
dc.date.issued2012-10
dc.description.abstractColorectal cancer (CRC) is the most common tumour type in both sexes combined in Western countries. Although screening programmes including the implementation of faecal occult blood test and colonoscopy might be able to reduce mortality by removing precursor lesions and by making diagnosis at an earlier stage, the burden of disease and mortality is still high. Improvement of diagnostic and treatment options increased staging accuracy, functional outcome for early stages as well as survival. Although high quality surgery is still the mainstay of curative treatment, the management of CRC must be a multi-modal approach performed by an experienced multi-disciplinary expert team. Optimal choice of the individual treatment modality according to disease localization and extent, tumour biology and patient factors is able to maintain quality of life, enables long-term survival and even cure in selected patients by a combination of chemotherapy and surgery. Treatment decisions must be based on the available evidence, which has been the basis for this consensus conference-based guideline delivering a clear proposal for diagnostic and treatment measures in each stage of rectal and colon cancer and the individual clinical situations. This ESMO guideline is recommended to be used as the basis for treatment and management decisions.
dc.identifier.doi10.1093/annonc/mds236
dc.identifier.eissn1569-8041
dc.identifier.issn0923-7534
dc.identifier.pubmed23012255
dc.identifier.urihttps://hdl.handle.net/11424/245466
dc.identifier.wosWOS:000309412700003
dc.language.isoeng
dc.publisherELSEVIER
dc.relation.ispartofANNALS OF ONCOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMETASTATIC COLORECTAL-CANCER
dc.subjectCAPECITABINE PLUS OXALIPLATIN
dc.subjectRANDOMIZED PHASE-III
dc.subjectANGIOGENESIS INHIBITOR BEVACIZUMAB
dc.subjectGROWTH-FACTOR RECEPTOR
dc.subjectLIVER-ONLY METASTASES
dc.subjectGENE MUTATION STATUS
dc.subjectLONG-TERM SURVIVAL
dc.subject1ST-LINE TREATMENT
dc.subjectADJUVANT CHEMOTHERAPY
dc.titleESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage2516
oaire.citation.issue10
oaire.citation.startPage2479
oaire.citation.titleANNALS OF ONCOLOGY
oaire.citation.volume23

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
838.01 KB
Format:
Adobe Portable Document Format